TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04482907

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Giving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.
Description: Tests from intravenous blood: TSH, fT3, fT4, anti-TPO, Anti-Tg, CRP

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Giving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.
Description: Tests from intravenous blood: TSH, fT3, fT4, anti-TPO, Anti-Tg, CRP
Study: NCT01330550

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber sugar free biscuit
Description: Dosage form:Biscuit, Dosage:1.94gram fiber/slice, Frequency:9 slices/meal;3 times/day. Duration:8 weeks
Study: NCT01221558

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lycopene

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lycopene

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lycopene
Study: NCT00497146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: 2 µg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule
Study: NCT02634619

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventral buccal mucosa onlay urethroplasty
Description: Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal buccal mucosa onlay urethroplasty
Description: Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
Study: NCT02413671

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Lupin Protein
Description: Subjects received a standardized test meal rich in carbohydrates and supplemented with lupin protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey Protein
Description: Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.

Intervention type: OTHER
Group type: OTHER
Intervention: Reference
Description: Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.
Study: NCT03628833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incontinence Management System
Description: Incontinence detection device
Study: NCT04418141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1
Description: Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
Study: NCT03336541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine (0.5 mg/kg in 100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
Study: NCT03714100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance
Description: Participants will attend one-hour Tai Ji Quan: Moving for Better Balance classes twice a week for 16-weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
Study: NCT03287700

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered to any group in this observational study.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered to any group in this observational study.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered to any group in this observational study.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered to any group in this observational study.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered to any group in this observational study.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered to any group in this observational study.
Study: NCT03982966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids (fish oil) 1000 mg/day oral
Description: Omega 3 fatty acids (fish oil) 1000 mg/day oral
Study: NCT02204644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib 600mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib 400mg qd
Study: NCT02349139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN001: Escalating dose Part A
Description: Androgen inhibitor
Study: NCT02562599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed-cisplatin
Description: Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
Study: NCT01085422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888
Study: NCT01502956

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InterStim® device
Description: Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox® injection
Description: Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
Study: NCT01909843

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171
Description: Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
Study: NCT00753298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric Primo (POBE) single-use urinary catheter
Description: LoFric Primo (POBE) single-use urinary catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LoFric Primo (PVC) single-use urinary catheter
Description: LoFric Primo (PVC) single-use urinary catheter
Study: NCT02510716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SGR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support message only

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support message only
Study: NCT03015090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
Study: NCT04529109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A investigational cosmetic lens 1
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A investigational cosmetic lens 1
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A investigational cosmetic lens 2
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A investigational cosmetic lens 2
Description: CONTROL
Study: NCT04297228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step by Step: A Family-Centered Healthy Lifestyle Intervention
Study: NCT01623128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal video
Description: Participants are randomized to view either the intervention video or a sham video.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prenatal video
Description: Participants are randomized to view either the intervention video or a sham video.
Study: NCT00989261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound AC220
Description: Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound AC220
Description: Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
Study: NCT01921426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
Study: NCT01968382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM 124-E (Hyperimmune Bovine Colostrum)
Description: Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM 124-E (Hyperimmune Bovine Colostrum)
Description: Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (High protein milk powder)
Description: Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (High protein milk powder)
Description: Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
Study: NCT02745951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliox
Description: Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.
Study: NCT04549064

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosis of pancreatic cancer
Description: Diagnosis of pancreatic cancer based on the concentration of serum biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosis of pancreatic cancer
Description: Diagnosis of pancreatic cancer based on the concentration of serum biomarkers
Study: NCT01624766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study: NCT04059796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega Gemini III Rev 2 Device
Description: Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Eye
Description: Control eyes will receive an approved monofocal or toric IOL post cataract extraction
Study: NCT03493737

Intervention type: BEHAVIORAL
Intervention: Quality of life surveys
Description: Quality of life surveys by EQ-5D and QLQ-C30

Intervention type: BEHAVIORAL
Intervention: Quality of life surveys
Description: Quality of life surveys by EQ-5D and QLQ-C30
Study: NCT04219202

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton radiation
Description: Therapeutic radiation Treatment with Protons

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion radiation
Description: Therapeutic radiation Treatment with Carbon Ions
Study: NCT01611090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine hydrochloride
Description: Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=capsule, route=oral use. Capsule is taken once daily continuously.
Study: NCT01829464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-875 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 tablets
Study: NCT02850068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization
Description: Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
Study: NCT00661999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Given by injection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous sulfate
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium ferric gluconate complex in sucrose
Description: Given by IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given by mouth
Study: NCT02238223

Intervention type: DRUG
Intervention: Alesion®
Study: NCT02285127

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short versus long cephalomedullary Intramedullary nail
Description: Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short versus long cephalomedullary Intramedullary nail
Description: Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.
Study: NCT01915732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duac™Once Daily Gel
Description: 1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% clindamycin phosphate gel
Description: 1% clindamycin as clindamycin phosphate
Study: NCT03352427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 60 mg/m2 orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml
Study: NCT00417690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Aminosalicylic acid
Description: Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PASER placebo granules
Description: Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
Study: NCT02716129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine plus Nalbuphine
Description: 39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
Study: NCT01180595

Intervention type: DEVICE
Group type: OTHER
Intervention: Trabecular Metal Modular Tibial Total Knee Component
Description: The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.

Intervention type: DEVICE
Group type: OTHER
Intervention: Trabecular Metal Monoblock Tibial Total Knee Component
Study: NCT00617110

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: live attenuated influenza virus (LAIV) with clean air
Description: Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: live attenuated influenza virus (LAIV) with clean air
Description: Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LAIV and diesel exhaust particles
Description: subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: LAIV and diesel exhaust particles
Description: subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
Study: NCT02419690

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: text message intervention
Description: Subjects will be sent 58 messages (3-5 per week) over 12 weeks, plus reminder messages for follow up interviews. The content of these messages will focus on contraception methods and effectiveness, sexually transmitted infection (STI) transmission, condom use, partner and parental communication, and healthy relationships. There will also be several text messages asking the participant if they would like to have a health educator contact them. The format will include facts, quizzes, true/false and some will have links to videos/pictures and websites, and some will request a response.
Study: NCT01217086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.